CWC
MRNS

Carolinas Wealth Consulting’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Carolinas Wealth Consulting’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-423
Closed -$1.68K – 1130
2022
Q4 		$1.68K Hold
423
– – ﹤0.01% 828
2022
Q3 		$3K Hold
423
– – ﹤0.01% 745
2022
Q2 		$2K Hold
423
– – ﹤0.01% 791
2022
Q1 		$4K Hold
423
– – ﹤0.01% 741
2021
Q4 		$5K Buy
+423
New +$4.88K ﹤0.01% 719

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Carolinas Wealth Consulting's MRNS Position: Q1 2023 in Review

Carolinas Wealth Consulting sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2023, closing a stake of 423 shares — an estimated $1.68K sold.

Carolinas Wealth Consulting first reported a position in MRNS in Q4 2021 and held it in 5 quarters. The position peaked at $5K in Q4 2021. 86 funds tracked by Wall St. Rank hold MRNS as of Q1 2023.

  • Carolinas Wealth Consulting reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 423 Marinus Pharmaceuticals, Inc shares in Q1 2023, an estimated $1.68K.
  • Carolinas Wealth Consulting first reported a position in Marinus Pharmaceuticals, Inc in Q4 2021 and held it in 5 quarters.
  • Carolinas Wealth Consulting's Marinus Pharmaceuticals, Inc position peaked at $5K in Q4 2021.
  • 86 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2023.

Based on Carolinas Wealth Consulting's 13F filing for Q1 2023, filed 16 May 2023.